FDA Approves Regeneron’s First Gene Therapy for Hearing Loss
Regeneron Makes History: FDA Approves Otarmeni, the First Gene Therapy for Rare Genetic Hearing Loss NEW YORK — In a landmark victory for precision medicine, the U.S. Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ Otarmeni, marking the first time a gene therapy for hearing loss has been cleared for clinical use. … Read more